Irving H. Fox

16.0k total citations · 6 hit papers
194 papers, 12.1k citations indexed

About

Irving H. Fox is a scholar working on Molecular Biology, Epidemiology and Genetics. According to data from OpenAlex, Irving H. Fox has authored 194 papers receiving a total of 12.1k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Molecular Biology, 86 papers in Epidemiology and 48 papers in Genetics. Recurrent topics in Irving H. Fox's work include Biochemical and Molecular Research (92 papers), Inflammatory Bowel Disease (45 papers) and Cytomegalovirus and herpesvirus research (40 papers). Irving H. Fox is often cited by papers focused on Biochemical and Molecular Research (92 papers), Inflammatory Bowel Disease (45 papers) and Cytomegalovirus and herpesvirus research (40 papers). Irving H. Fox collaborates with scholars based in United States, Canada and France. Irving H. Fox's co-authors include William N. Kelley, Brian G. Feagan, Asit Parikh, Catherine Milch, William J. Sandborn, Bruce E. Sands, Serap Sankoh, Jean‐Frédéric Colombel, Paul Rutgeerts and Jing Xu and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Irving H. Fox

190 papers receiving 11.5k citations

Hit Papers

Vedolizumab as Inducti... 1978 2026 1994 2010 2013 2013 2016 2005 2014 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
    2013 2.0k citations Brian G. Feagan, Paul Rutgeerts et al. New England Journal of Medicine profile →
  2. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
    2013 2.0k citations William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine profile →
  3. The safety of vedolizumab for ulcerative colitis and Crohn's disease
    2016 563 citations Jean‐Frédéric Colombel, Bruce E. Sands et al. Gut profile →
  4. Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
    2005 535 citations Brian G. Feagan, Gordon R. Greenberg et al. New England Journal of Medicine profile →
  5. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
    2014 531 citations Bruce E. Sands, Brian G. Feagan et al. Gastroenterology profile →
  6. The Role of Adenosine and 2'-Deoxyadenosine in Mammalian Cells
    1978 444 citations Irving H. Fox et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Irving H. Fox United States 45 5.9k 5.9k 3.5k 2.6k 2.2k 194 12.1k
Geoffrey W. McCaughan Australia 73 8.4k 1.4× 946 0.2× 3.1k 0.9× 3.4k 1.3× 5.2k 2.4× 528 20.3k
Naoyuki Kamatani Japan 58 1.5k 0.3× 1.4k 0.2× 5.3k 1.5× 2.5k 1.0× 1.6k 0.7× 344 13.5k
Manikkam Suthanthiran United States 56 1.8k 0.3× 731 0.1× 3.1k 0.9× 2.9k 1.1× 3.2k 1.5× 227 12.6k
Paul H. Plötz United States 63 5.6k 1.0× 1.1k 0.2× 3.3k 0.9× 2.7k 1.0× 750 0.3× 183 12.7k
Diego Vergani United Kingdom 73 11.2k 1.9× 1.8k 0.3× 1.2k 0.3× 4.0k 1.5× 4.1k 1.9× 417 19.0k
Geoffrey Neale United States 59 1.9k 0.3× 1.1k 0.2× 7.3k 2.1× 6.6k 2.6× 992 0.5× 171 15.3k
Hal M. Hoffman United States 60 4.1k 0.7× 727 0.1× 11.9k 3.4× 6.5k 2.5× 2.2k 1.0× 152 17.8k
Lucienne Chatenoud France 59 1.1k 0.2× 4.4k 0.7× 1.3k 0.4× 5.9k 2.3× 3.1k 1.4× 272 11.4k
Tooru Shimosegawa Japan 80 7.1k 1.2× 2.2k 0.4× 5.3k 1.5× 3.2k 1.2× 13.2k 6.1× 702 25.7k
Ernst Holler Germany 63 1.8k 0.3× 1.1k 0.2× 3.1k 0.9× 6.6k 2.5× 1.2k 0.5× 370 16.6k

Countries citing papers authored by Irving H. Fox

Since Specialization
Citations

This map shows the geographic impact of Irving H. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irving H. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irving H. Fox more than expected).

Fields of papers citing papers by Irving H. Fox

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irving H. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irving H. Fox. The network helps show where Irving H. Fox may publish in the future.

Co-authorship network of co-authors of Irving H. Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Irving H. Fox. A scholar is included among the top collaborators of Irving H. Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irving H. Fox. Irving H. Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Colombel, Jean‐Frédéric, Bruce E. Sands, Paul Rutgeerts, et al.. (2016). The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 66(5). 839–851. 563 indexed citations breakdown →
2.
Rosario, Maria, Timothy Wyant, Timothy Leach, et al.. (2016). Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers. Clinical Drug Investigation. 36(11). 913–923. 38 indexed citations
3.
Feagan, B G, William J. Sandborn, Matthew D. Smyth, et al.. (2014). P501 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Journal of Crohn s and Colitis. 8. S276–S277. 8 indexed citations
4.
Sandborn, W., Brian G. Feagan, Walter Reinisch, et al.. (2014). P497 Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6. Journal of Crohn s and Colitis. 8. S274–S275. 9 indexed citations
5.
Sands, Bruce E., Brian G. Feagan, Paul Rutgeerts, et al.. (2014). Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. Gastroenterology. 147(3). 618–627.e3. 531 indexed citations breakdown →
6.
Parikh, Asit, Irving H. Fox, Timothy Leach, et al.. (2013). Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 19(8). 1691–1699. 70 indexed citations
7.
Feagan, Brian G., Paul Rutgeerts, Bruce E. Sands, et al.. (2013). Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 369(8). 699–710. 2048 indexed citations breakdown →
8.
Milch, Catherine, et al.. (2012). P234 Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers. Journal of Crohn s and Colitis. 6. S102–S103. 7 indexed citations
9.
Parikh, Asit, Timothy Leach, Tim Wyant, et al.. (2011). Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study. Inflammatory Bowel Diseases. 18(8). 1470–1479. 182 indexed citations
10.
Feagan, Brian G., Gordon R. Greenberg, Gary Wild, et al.. (2005). Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin. New England Journal of Medicine. 352(24). 2499–2507. 535 indexed citations breakdown →
11.
Hutchison, Kevin A., et al.. (1991). Properties of Adenotin Reconstituted into Phospholipid Vesicles. The American Journal of the Medical Sciences. 301(1). 1–8. 1 indexed citations
12.
13.
Hutchison, Kevin A., et al.. (1989). Characteristics of an adenosine A1 binding site in human placental membranes. Archives of Biochemistry and Biophysics. 268(1). 191–202. 12 indexed citations
14.
Datta, N S, Donna S. Shewach, Mary C. Hurley, Beverly S. Mitchell, & Irving H. Fox. (1989). Properties of Highly Purified Human T Lymphoblast (Molt-4) Deoxycytidine Kinase. Advances in experimental medicine and biology. 253B. 87–92. 1 indexed citations
15.
Tekkanat, Kim K. & Irving H. Fox. (1988). Isocratic separation of ATP and its degradation products from biological fluids by automated liquid chromatography.. Clinical Chemistry. 34(5). 925–932. 37 indexed citations
16.
Braunstein, Ethan M., et al.. (1987). Radiologic features of a pyrophosphate-like arthropathy associated with long-term dialysis. Skeletal Radiology. 16(6). 437–441. 15 indexed citations
17.
Lambert, John, Moshe Shike, Irving H. Fox, & K.N. Jeejeebhoy. (1980). Uric acid metabolism in patients receiving total parenteral nutrition (TPN).. Gastroenterology. 78. 2 indexed citations
18.
Gelfand, Erwin W., et al.. (1978). Normal B-lymphocyte function in patients with Lesch-Nyhan syndrome and HGPRT deficiency.. PubMed Central. 31(2). 205–8. 8 indexed citations
19.
Dwosh, Isaac L., Daniel A. K. Roncari, Errol B. Marliss, & Irving H. Fox. (1977). Hypouricemia in disease: a study of different mechanisms.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 90(1). 153–61. 23 indexed citations
20.
Fox, Irving H., et al.. (1969). The Sixty-minute Plasma Phenolsulfonphthalein Concentration as a Test of Renal Function. American Journal of Clinical Pathology. 52(3). 345–350. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Geoffrey W. McCaughan Breakdown of academic impact, for papers by Naoyuki Kamatani Breakdown of academic impact, for papers by Manikkam Suthanthiran Breakdown of academic impact, for papers by Paul H. Plötz Breakdown of academic impact, for papers by Diego Vergani Breakdown of academic impact, for papers by Geoffrey Neale Breakdown of academic impact, for papers by Hal M. Hoffman Breakdown of academic impact, for papers by Lucienne Chatenoud Breakdown of academic impact, for papers by Tooru Shimosegawa Breakdown of academic impact, for papers by Ernst Holler
Rankless by CCL
2026